We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Non-small Cell Lung Cancer and Quality of Life (SILKE)

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: January 7, 2009
Last Update Posted: May 29, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Maria Silvoniemi, University of Turku
The principal objective is to study clinical observations, symptoms and quality of life of non-small-cell lung cancer (NSCLC) patients undergoing specific non-operative treatment for cancer, including chemotherapy and radiotherapy.

Non Small Cell Lung Cancer

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Treatment of Non-small Cell Lung Cancer -Effects on Quality of Life and Symptom Control

Resource links provided by NLM:

Further study details as provided by Maria Silvoniemi, University of Turku:

Biospecimen Retention:   Samples With DNA
whole blood

Enrollment: 130
Study Start Date: August 2008
Study Completion Date: February 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Non-small cell lung cancer patients


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The patients treated in the clinic of respiratory medicine in Turku, Finland

Inclusion Criteria:

  • Patients with verified NSCLC
  • after the NSCLC diagnosis has been confirmed prior to first chemotherapy or radiotherapy
  • Finnish speaking patients
  • aged 18 years or more
  • Written informed consent has to be signed

Exclusion Criteria:

  • Patients not consenting to participate in the study
  • patients not able to communicate sufficiently
  • cancer type is other than non-small-cell lung cancer
  Contacts and Locations
No Contacts or Locations Provided
  More Information

Responsible Party: Maria Silvoniemi, MD, University of Turku
ClinicalTrials.gov Identifier: NCT00818402     History of Changes
Other Study ID Numbers: SILKE-ETMK:47/180/2008
First Submitted: January 5, 2009
First Posted: January 7, 2009
Last Update Posted: May 29, 2015
Last Verified: May 2015

Keywords provided by Maria Silvoniemi, University of Turku:
Quality of life

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms